# Egypt signs agreement to transfer PCV-20 vaccine technology from Minhai

> Egypt’s GennVax and China’s Minhai signed a partnership agreement to transfer PCV-20 pneumococcal vaccine manufacturing technology to Egypt. The Egyptian Drug Authority said the agreement is intended to localize production of priority vaccines.

- Canonical URL: https://newsverum.com/en/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement
- Publisher: Newsverum
- Section: Health
- Country: Egypt
- Published: 2026-10-06T17:11:49+00:00
- Updated: 2026-10-07T00:57:36+03:00
- Event / data period: 2026-10-01
- Other editions: [Türkçe](https://newsverum.com/tr/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md), [العربية](https://newsverum.com/ar/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md), [Français](https://newsverum.com/fr/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md), [Español](https://newsverum.com/es/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md), [Deutsch](https://newsverum.com/de/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md), [Português](https://newsverum.com/pt/news/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement.md)

EDA chairman Ali El-Ghamrawy witnessed the signing during a visit to Minhai’s facilities in China on October 1. He toured the company’s PCV-13 production line, and the parties also discussed possible technology transfer and technical expertise exchange.

The authority connected the agreement to Egypt’s 2024–2030 vaccine-manufacturing strategy. It said the partnership aims to develop capacity and expertise, support pharmaceutical supply security and expand access to regional and international markets; it did not announce a production start date or volume.

## Data

### PCV-20 vaccine technology transfer agreement

GennVax–Minhai agreement as announced by EDA

Methodology: The announced agreement transfers PCV-20 manufacturing technology; no production start date or volume was stated.

| Fact | Source-reported finding |
|---|---|
| Egyptian partner | GennVax |
| Chinese partner | Minhai |
| Technology covered | PCV-20 pneumococcal vaccine manufacturing |
| Announced strategic framework | Egypt national vaccine manufacturing strategy, 2024–2030 |

Sources: <https://sis.gov.eg/en/media-center/news/gennvax-minhai-sign-deal-to-transfer-pneumococcal-vaccine-technology/> · Download data: [JSON](https://newsverum.com/api/v1/articles/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement/data/d-egypt-localizes-pcv20-vaccine-technolo?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/egypt-localizes-pcv20-vaccine-technology-with-minhai-agreement/data/d-egypt-localizes-pcv20-vaccine-technolo?lang=en&format=csv)

## Sources

- [Egypt State Information Service, citing the Egyptian Drug Authority](<https://sis.gov.eg/en/media-center/news/gennvax-minhai-sign-deal-to-transfer-pneumococcal-vaccine-technology/>) (Source checked: 2026-10-06; Published: 2026-10-01)

## Correction history

- 2026-10-07T00:49:25+03:00: German and Portuguese editions and translations of the data and correction explanations have been added to this article.
- 2026-10-07T00:57:36+03:00: The article’s language editions and data explanations were reviewed, and identified translation and label issues were corrected. Sources, numerical data and the first-publication date were preserved.

---

Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)